<DOC>
	<DOCNO>NCT01719302</DOCNO>
	<brief_summary>Chemotherapy treatment docetaxel gemcitabine standard treatment patient soft tissue sarcoma . This study design explore whether addition tyrosine kinase inhibitor pazopanib enhance anticancer effect chemotherapy drug . The Phase I component study design determine maximum tolerate dose pazopanib give docetaxel gemcitabine . The Phase II component design determine overall response rate combination docetaxel , gemcitabine pazopanib prior surgical resection patient soft tissue sarcoma .</brief_summary>
	<brief_title>Docetaxel , Gemcitabine Pazopanib Treatment Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>18 year old chemotherapy naive , histologically high grade soft tissue sarcoma consider operable tumor great 5 cm long dimension life expectancy least 6 month Zubrod performance status 02 sign inform consent adequate bone marrow function define : 1. absolute peripheral granulocyte count &gt; 1500 cells/mm^3 2. hemoglobin &gt; 8.0 g/dl 3. platelet count &gt; 100,000/mm^3 4. absence regular red blood cell transfusion requirement adequate hepatic function define : 1. total bilirubin &lt; 1.5 x upper limit normal ( ULN ) 2 . AST , ALT alkaline phosphatase 2.5 x ULN adequate renal function define : 1. serum creatinine &lt; 1.5 x ULN negative pregnancy test woman child bear potential willingness use effective contraception treatment 3 month thereafter Multiple metastasis ( patient 5 few oligometastases could resectable eligible ) Pregnant woman nurse mother concurrent chemotherapy radiation therapy severe medical problem ( discretion investigator ) history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 symptomatic brain metastasis cirrhosis dermatofibrosarcoma protuberans ( DFSP ) , embryonal rhabdomyosarcoma alveolar soft part sarcoma ( ASPS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Soft tissue sarcoma</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>docetaxel</keyword>
	<keyword>pazopanib</keyword>
</DOC>